The Greater Phoenix CCOP is a consortium of five hospitals with 40 investigators, led by principal investigator, David King, MD. Dr. King and many of the investigators have been associated with the CCOP since its inception in 1982. The continuing long-term goals and specific aims of the GPCCOP include: 1) To increase clinical research activities with new and established research bases; 2) To participate in chemoprevention studies supported through other NCI mechanisms, to enhance offerings to GPCCOP's population; 4) To maintain and enhance quality assurance and pharmacy tools to support GPCCOP accrual; 5) To provide for human subject protection and minimal research risk; and 6) To support the disease prevention objectives of """"""""Healthy People 2010"""""""" - in particular, to eliminate health disparities among different segments of the population through outreach, affiliations, and recruitment strategies focusing on minorities, women, and the underserved. GPCCOP's organizational structure requires the involvement of the investigators, hospital administrators from each of the participating component organizations and the staff in planning and policy-making decisions. The research activities and resources are split evenly between the treatment segment and the chemoprevention segment of GPCCOP, with each segment achieving accrual and quality goals established by the National Cancer Institute. GPCCOP's outreach is focused on achieving goals of minority and underserved accrual through community affiliations, collaborations, and geographical diversity. By establishing community and tribal partnerships, GPCCOP facilitates an outreach territory encompassing more that 40,000 square miles and 4 counties. GPCCOP's dedication to participant accrual (205 treatment and more than 1000 chemoprevention participants in the past five years), quality assurance, human subject protection, and minority outreach, as well as the devotion of resources from its consortium hospitals, demonstrate its preparedness to continue its active participation in NCI's Community Clinical Oncology Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035262-21
Application #
6786043
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Sgambati, Maria
Project Start
1983-09-01
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
21
Fiscal Year
2004
Total Cost
$562,644
Indirect Cost
Name
Banner Good Samaritan Medical Center
Department
Type
DUNS #
110443561
City
Phoenix
State
AZ
Country
United States
Zip Code
85006
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13

Showing the most recent 10 out of 67 publications